Brief: Gilead Sciences Exercises Option To License Assembly Biosciences’ Helicase-Primase Inhibitor Programs For Recurrent Genital Herpes
22/12/2025 13:20
Dec 22 (Reuters) - Assembly Biosciences Inc ASMB.O: GILEAD SCIENCES EXERCISES OPTION TO LICENSE ASSEMBLY BIOSCIENCES’ HELICASE-PRIMASE INHIBITOR PROGRAMS FOR RECURRENT GENITAL HERPES GILEAD - ASSEMBLY BIO TO RECEIVE $35 MILLION FOR GILEAD'S HSV OPTION Source text: ID:nBw9s5GZKa Further company coverage: ASMB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Assembly Biosciences
See all newsAssembly Biosciences Q1 revenue falls, net loss widens
Assembly Biosciences 2025 net loss narrows
Assembly Biosciences rises as Gilead opts to license co's HSV therapies
Brief: Gilead Sciences Exercises Option To License Assembly Biosciences’ Helicase-Primase Inhibitor Programs For Recurrent Genital Herpes
Assembly Biosciences Q3 net loss narrows, raises $175 mln